Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

M Goetz; M Ames; M Gnant; M Filpits; R Jakesz; Richard Greil; C Marth; H Samonigg; V Suman; S Safgren; M Kuffel; R Weinshilboum; M Erlander; XJ Ma; J Ingle

Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

M Goetz, M Ames, M Gnant, M Filpits, R Jakesz, Richard Greil, C Marth, H Samonigg, V Suman, S Safgren, M Kuffel, R Weinshilboum, M Erlander, XJ Ma, J Ingle

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	77S-77S
Journal	CANCER RESEARCH
Volume	69
Issue number	2
Publication status	Published - 2009
Event	31st Annual San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 10 Jan 2008 → 14 Jan 2008

Cite this

Goetz, M., Ames, M., Gnant, M., Filpits, M., Jakesz, R., Greil, R., Marth, C., Samonigg, H., Suman, V., Safgren, S., Kuffel, M., Weinshilboum, R., Erlander, M., Ma, XJ., & Ingle, J. (2009). Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. CANCER RESEARCH , 69(2), 77S-77S.

Goetz, M ; Ames, M ; Gnant, M et al. / Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. In: CANCER RESEARCH 2009 ; Vol. 69, No. 2. pp. 77S-77S.

@article{25f02d34dc0d458e9368ce7f05970b01,

title = "Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.",

author = "M Goetz and M Ames and M Gnant and M Filpits and R Jakesz and Richard Greil and C Marth and H Samonigg and V Suman and S Safgren and M Kuffel and R Weinshilboum and M Erlander and XJ Ma and J Ingle",

year = "2009",

language = "English",

volume = "69",

pages = "77S--77S",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "2",

note = "31st Annual San Antonio Breast Cancer Symposium ; Conference date: 10-01-2008 Through 14-01-2008",

}

Goetz, M, Ames, M, Gnant, M, Filpits, M, Jakesz, R, Greil, R, Marth, C, Samonigg, H, Suman, V, Safgren, S, Kuffel, M, Weinshilboum, R, Erlander, M, Ma, XJ & Ingle, J 2009, 'Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.', CANCER RESEARCH , vol. 69, no. 2, pp. 77S-77S.

Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. / Goetz, M; Ames, M; Gnant, M et al.
In: CANCER RESEARCH , Vol. 69, No. 2, 2009, p. 77S-77S.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

AU - Goetz, M

AU - Ames, M

AU - Gnant, M

AU - Filpits, M

AU - Jakesz, R

AU - Greil, Richard

AU - Marth, C

AU - Samonigg, H

AU - Suman, V

AU - Safgren, S

AU - Kuffel, M

AU - Weinshilboum, R

AU - Erlander, M

AU - Ma, XJ

AU - Ingle, J

PY - 2009

Y1 - 2009

M3 - Abstract (Journal)

SN - 0008-5472

VL - 69

SP - 77S-77S

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 2

T2 - 31st Annual San Antonio Breast Cancer Symposium

Y2 - 10 January 2008 through 14 January 2008

ER -

Goetz M, Ames M, Gnant M, Filpits M, Jakesz R, Greil R et al. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. CANCER RESEARCH . 2009;69(2):77S-77S.